Abivax Socit Anonyme Stock Ten Year Return
ABIVAX Socit Anonyme fundamentals help investors to digest information that contributes to ABIVAX Société's financial success or failures. It also enables traders to predict the movement of ABIVAX Pink Sheet. The fundamental analysis module provides a way to measure ABIVAX Société's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ABIVAX Société pink sheet.
ABIVAX |
ABIVAX Socit Anonyme Company Ten Year Return Analysis
ABIVAX Société's Ten Year Return shows the total annualized return generated from holding a fund for the last 10 years and represents fund's capital appreciation, including dividends losses and capital gains distributions. This return indicator is considered by many investors to be the ultimate measures of fund performance and can reflect the overall performance of the market or market segment it invests in.
More About Ten Year Return | All Equity Analysis
Ten Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Ten Year Fund Return indicator can give a sense of overall fund long-term potential, it is recommended to compare funds performances against other similar funds or market benchmarks for the same 10-year interval.
CompetitionBased on the latest financial disclosure, ABIVAX Socit Anonyme has a Ten Year Return of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Idea Breakdown Now
Idea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
All Next | Launch Module |
ABIVAX Fundamentals
Return On Equity | -12.86 | |||
Return On Asset | -0.44 | |||
Operating Margin | 4.66 % | |||
Current Valuation | 165.28 M | |||
Shares Outstanding | 22.3 M | |||
Shares Owned By Insiders | 4.67 % | |||
Shares Owned By Institutions | 57.27 % | |||
Price To Earning | (7.88) X | |||
Price To Book | 27.57 X | |||
Price To Sales | 20.65 X | |||
Revenue | 37 K | |||
Gross Profit | (45.52 M) | |||
EBITDA | (42.25 M) | |||
Net Income | (41.36 M) | |||
Cash And Equivalents | 26.57 M | |||
Cash Per Share | 1.58 X | |||
Total Debt | 53.45 M | |||
Debt To Equity | 8.03 % | |||
Current Ratio | 2.03 X | |||
Book Value Per Share | 0.36 X | |||
Cash Flow From Operations | (45.66 M) | |||
Earnings Per Share | (2.59) X | |||
Number Of Employees | 24 | |||
Beta | 1.26 | |||
Market Capitalization | 165.36 M | |||
Total Asset | 110.36 M | |||
Z Score | 1.8 | |||
Net Asset | 110.36 M |
Currently Active Assets on Macroaxis
SGC | Superior Uniform Group | |
VLN | Valens | |
GNFT | Genfit | |
GAIA | Gaia Inc | |
BLBD | Blue Bird Corp |
Other Information on Investing in ABIVAX Pink Sheet
ABIVAX Société financial ratios help investors to determine whether ABIVAX Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ABIVAX with respect to the benefits of owning ABIVAX Société security.